Terms: = Prostate cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
70 results:
1. TrkA promotes mdm2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.
Zhang Y; Huang Z; Li K; Xie G; Feng Y; Wang Z; Li N; Liu R; Ding Y; Wang J; Yang J; Jia Z
J Exp Clin Cancer Res; 2024 Jan; 43(1):16. PubMed ID: 38200609
[TBL] [Abstract] [Full Text] [Related]
2. Synthesis and biological evaluation of dual mdm2/XIAP inhibitors based on the tetrahydroquinoline scaffold.
Albadari N; Xie Y; Liu T; Wang R; Gu L; Zhou M; Wu Z; Li W
Eur J Med Chem; 2023 Jul; 255():115423. PubMed ID: 37130471
[TBL] [Abstract] [Full Text] [Related]
3. Blockage of mdm2-mediated p53 ubiquitination by yuanhuacine restrains the carcinogenesis of prostate carcinoma cells by suppressing LncRNA LINC00665.
Yan M; Li X; Gu J; Gao G; Wu Z; Xue P
J Biochem Mol Toxicol; 2023 Mar; 37(3):e23265. PubMed ID: 36416364
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.
Kumari S; Sharma V; Tiwari R; Maurya JP; Subudhi BB; Senapati D
Eur J Pharmacol; 2022 Mar; 919():174807. PubMed ID: 35151649
[TBL] [Abstract] [Full Text] [Related]
5. Molecular imaging and treatment of PSMA-positive prostate cancer with
Jiao Y; Xu P; Luan S; Wang X; Gao Y; Zhao C; Fu P
Nucl Med Biol; 2022; 104-105():28-37. PubMed ID: 34847481
[TBL] [Abstract] [Full Text] [Related]
6. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin D
Klin Onkol; 2021; 34(3):220-234. PubMed ID: 34362257
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and epigenetic bases of prostate tumor cell radioresistance.
Kutilin Denis
Ceska Gynekol; 2021; 86(3):220-234. PubMed ID: 34192880
[TBL] [Abstract] [Full Text] [Related]
8.
Bai L; Li X; Ma X; Zhao R; Wu D
Anticancer Res; 2020 Nov; 40(11):6051-6062. PubMed ID: 33109543
[TBL] [Abstract] [Full Text] [Related]
9. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract] [Full Text] [Related]
10. Long non-coding RNA BLACAT1 inhibits prostate cancer cell proliferation through sponging miR-361.
Li HY; Jiang FQ; Chu L; Wei X
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):74-85. PubMed ID: 31957820
[TBL] [Abstract] [Full Text] [Related]
11. Regulation of cell cycle by mdm2 in prostate cancer cells through Aurora Kinase-B and p21WAF1
Kanagasabai T; Venkatesan T; Natarajan U; Alobid S; Alhazzani K; Algahtani M; Rathinavelu A
Cell Signal; 2020 Feb; 66():109435. PubMed ID: 31706019
[TBL] [Abstract] [Full Text] [Related]
12. TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
Feng T; Zhao R; Sun F; Lu Q; Wang X; Hu J; Wang S; Gao L; Zhou Q; Xiong X; Dong X; Wang L; Han B
Oncogene; 2020 Jan; 39(2):356-367. PubMed ID: 31477836
[TBL] [Abstract] [Full Text] [Related]
13. Emerging therapeutic targets for patients with advanced prostate cancer.
Saad F; Shore N; Zhang T; Sharma S; Cho HK; Jacobs IA
Cancer Treat Rev; 2019 Jun; 76():1-9. PubMed ID: 30913454
[TBL] [Abstract] [Full Text] [Related]
14. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
[TBL] [Abstract] [Full Text] [Related]
15. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
16. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the treatment of prostate cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract] [Full Text] [Related]
17. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1.
Zhu S; Zhao D; Yan L; Jiang W; Kim JS; Gu B; Liu Q; Wang R; Xia B; Zhao JC; Song G; Mi W; Wang RF; Shi X; Lam HM; Dong X; Yu J; Chen K; Cao Q
Nat Commun; 2018 Feb; 9(1):500. PubMed ID: 29402932
[TBL] [Abstract] [Full Text] [Related]
18. Co‑expression of murine double minute 2 siRNA and wild‑type p53 induces G1 cell cycle arrest in H1299 cells.
Liu L; Zhang P; Guo H; Tang X; Liu L; Li J; Guo R; Cai Y; Liu Y; Li Y
Mol Med Rep; 2017 Dec; 16(6):9137-9142. PubMed ID: 29039579
[TBL] [Abstract] [Full Text] [Related]
19. Triggering p53 activation is essential in ziyuglycoside I-induced human retinoblastoma WERI-Rb-1 cell apoptosis.
Zhu X; Wang K; Yao Y; Zhang K; Zhou F; Zhu L
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 28960612
[TBL] [Abstract] [Full Text] [Related]
20. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder cancer.
Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
[No Abstract] [Full Text] [Related]
[Next]
